Treatment of hepatorenal syndrome: Vasoconstriction or vasodilation? / 临床肝胆病杂志

ABSTRACT

Hepatorenal syndrome (HRS) is a serious complication that occurs in patients with decompensated cirrhosis or acute/chronic liver failure. The main pathological features of HRS include marked peripheral vasodilation and strong renal vasoconstriction, with rapid progression, unsatisfactory treatment response, and poor prognosis. Vasoconstrictors are mainly used in the pharmacotherapy for HRS, and at present, terlipressin combined with albumin is the first-line treatment method for HRS. Some drugs with a renal vasodilatory effect also show a potential therapeutic effect. This article reviews the latest research advances in the role and clinical application of vasoactive drugs in the treatment of HRS.